Gemtuzumab Ozogamicin (Mylotarg®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

Publisher： Karger

E-ISSN： 2296-5262|27|3|269-272

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.27, Iss.3, 2004-07, pp. : 269-272

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials

By  

Oncology Research and Treatment, Vol. 30, Iss. 12, 2007-11 ,pp. : 657-662

Karger

Access to resources Recommend Favorite

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia

By  

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 4036-4043

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia

By  

Oncology Research and Treatment, Vol. 24, Iss. 4, 2001-09 ,pp. : 356-360

Karger

Access to resources Recommend Favorite

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 325-334

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : 193-196

John Wiley & Sons Inc

Access to resources Recommend Favorite